Wednesday, September 21, 2016 8:29:50 PM
William Blair analyst John Sonnier is out with a research report on Exelixis, Inc. (NASDAQ:EXEL) as the biotech company’s shares have been shooting up 131% year-to-date, which Sonnier deems “a bright spot” amid “an extremely volatile sector.”
Investors have continued to call the analyst throughout the past two weeks, with a real spotlight of interest honing in on the almost release of positive Phase II CABOSUN full data. The trial evaluates EXEL’s pipeline drug Cabometyx, and where its safety and efficacy in intermediate or poor-risk front-line rental cell carcinoma (RCC) patients, 80% of the whole market, square up against competitor Sutent, Pfizer’s leading front-line prescription.
Sonnier forecasts this could prove to be an over $1 billion global market opportunity. The analyst increased both Cabometyx and Cometriq sales estimates from $109 million to $156 million in 2016, from $199 million to $308 million in 2017, and from $307 million to $405 million in 2018. Additionally, the analyst introduces a 2019 projection for $471 million.
Sonnier notes back on May 23rd, positive top-line data was released, and the analyst anticipates that come next month at the European Society of Medical Oncology (ESMO) conference on October 7th through 11th, detailed data will be on its way.
“In our view, Exelixis is a fundamentally improved and transformed company compared with just one year ago, with an investment profile that holds broader appeal. At current price levels, we believe that EXEL shares are undervalued with significant upside potential and numerous catalysts in the coming months,” Sonnier concludes.
Ahead of the full data, the analyst reiterates an Outperform rating on EXEL without listing a price target.
Recent EXEL News
- Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine • Business Wire • 09/16/2024 12:45:00 PM
- Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024 • Business Wire • 09/15/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2024 11:07:07 PM
- Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September • Business Wire • 08/28/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 11:35:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 12:18:41 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 11:12:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/14/2024 09:01:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 11:22:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 11:32:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 11:32:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 11:32:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 11:31:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2024 09:20:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/09/2024 09:18:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/08/2024 09:42:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/07/2024 08:17:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/07/2024 08:13:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/07/2024 08:11:54 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/06/2024 09:03:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:18:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:08:46 PM
- Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update • Business Wire • 08/06/2024 08:05:00 PM
- Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors • Business Wire • 08/06/2024 12:30:00 PM
- Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 • Business Wire • 07/23/2024 08:05:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM